[{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IND for COVID-19 with Opaganib Submitted to the FDA by RedHill Biopharma","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"RedHill Biopharma"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RedHill Biopharma's Second COVID-19 Candidate, RHB-107, Cleared by FDA for Phase 2\/3 Study in Symptomatic COVID-19 Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"RedHill Biopharma"},{"orgOrder":0,"company":"Omnix Medical","sponsor":"EIC Accelerator Programme","pharmaFlowCategory":"D","amount":"$13.0 million","upfrontCash":"Undisclosed","newsHeadline":"Omnix Medical Wins \u20ac10.8M in EIC Accelerator Funding","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"ISRAEL","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Omnix Medical"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Funding secures the advancement of Omnix Medical’s lead compound OMN6 through Phase I and II clinical trials. OMN6 is a novel antimicrobial peptide for treating life-threatening infections caused by Gram-negative bacteria.
RHB-107 has demonstrated strong inhibition of SARS-CoV-2 viral replication in a human bronchial cell model and targets a host cell component involved in viral replication, minimizing potential for resistance due to viral mutations.
Proposed study intended to evaluate the safety and efficacy of opaganib in up to 60 patients hospitalized with positive SARS-CoV-2 infection and pneumonia in the U.S.